Lumos Diagnostics Progresses Additional Pilot Sites With Urgent Care Operators For Respiratory Infection Testing Tool, Shares Jump 4%
MT Newswires Live
May 18
Lumos Diagnostics Holdings (ASX:LDX) progressed numerous additional pilot sites with new urgent care operators/chains for its FebriDx rapid point-of-care test for acute respiratory infections, according to a Monday Australian bourse filing.
The eight urgent care chains run by new operator ownership groups are progressing favourably in their evaluation and implementation of FebriDx, it added.
Lumos is also receiving regular reimbursement updates through its consultants, PRO-spectus and AcuityMD, and is beginning to see early data from sites using FebriDx, which suggests that over 90% of submitted claims are being reimbursed.
Its shares rose 4% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.